Research programme: chimeric antigen receptor T cell therapies - CRISPR Therapeutics

Drug Profile

Research programme: chimeric antigen receptor T cell therapies - CRISPR Therapeutics

Alternative Names: Allogeneic CAR T-cell therapy - CRISPR Therapeutics; Anti-BCMA CAR-T cells - CRISPR Therapeutics; Anti-CD70 CAR-T cells - CRISPR Therapeutics; CRISPR-based CAR-T cell therapies - CRISPR Therapeutics; CTX 101 - CRISPR Therapeutics; CTX 110; CTX 120; CTX 130

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CRISPR Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 07 Aug 2018 CRISPR Therapeutics announces intention to submit IND application for CTX 110 for Haematological malignancies in late 2018
  • 16 Apr 2018 Preclinical trials in Solid tumours in Switzerland (Parenteral) before April 2018
  • 10 Nov 2017 CRISPR Therapeutics plans clinical development of CTX 110 for Haematological malignancies in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top